Kimball Electronics, Inc. (KE) Q4 2025 Earnings Conference Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a robust strategy with new facility expansion, strong focus on the medical segment, and margin improvement efforts. The Q&A reveals positive sentiment towards automation and growth initiatives, despite some vague responses on industrial plans. The reiteration of fiscal guidance, coupled with strategic investments in sales and business development, supports a positive outlook. The absence of negative financial surprises and the focus on high-growth segments suggest a positive stock price movement in the short term.
Key Financial Performance
Net Sales (Q4) $381 million, an 8% decline compared to Q4 last year when excluding the automation, test and measurement business that was divested. The decline was due to divestiture and lower sales in Automotive and Industrial segments, partially offset by growth in the Medical segment.
Medical Segment Sales (Q4) $107 million, up 5% compared to the same period last year. The increase was driven by a step-up in sales with the largest medical customer after a long period of decline during the FDA recall.
Automotive Segment Sales (Q4) $184 million, a 13% decrease compared to the fourth quarter of last year. The decline was driven by the electronic braking program no longer being produced in Reynosa and lower demand for electronic steering systems for EVs.
Industrial Segment Sales (Q4) $90 million, down 12% year-over-year when excluding AT&M. Declines were broad-based in North America and Europe, with Asia being flat.
Gross Margin Rate (Q4) 8%, a 50 basis point decrease compared to 8.5% in the same period of fiscal 2024. The decline was due to lower absorption and reduced year-over-year sales.
Adjusted Selling and Administrative Expenses (Q4) $10.8 million, a $3.2 million or 23% reduction compared to $14 million in Q4 last year. The decrease was due to cost reduction efforts, reduced bonus expense, and the absence of AT&M expenses.
Adjusted Operating Income (Q4) $19.6 million or 5.2% of net sales, compared to $22.7 million or 5.3% of net sales last year. The decline was due to lower sales, but it marked the third consecutive quarter of growth in absolute dollars and as a percentage of net sales.
Adjusted Net Income (Q4) $8.4 million or $0.34 per diluted share, compared to $9.7 million or $0.38 per diluted share last year. The decline was due to lower sales and higher tax rates.
Cash and Cash Equivalents (End of Q4) $88.8 million. Cash generated by operating activities in the quarter was $78.1 million, marking the sixth consecutive quarter of positive cash flow.
Inventory (End of Q4) $273.5 million, a $23.1 million reduction compared to Q3 and $64.6 million or 19% lower than a year ago. The reduction was due to working capital initiatives.
Borrowings (End of Q4) $147.5 million, a $31.3 million reduction from Q3 and down $147.3 million or 50% from the beginning of the fiscal year. The reduction was due to positive cash flow and debt repayment.
Capital Expenditures (Q4) $9.6 million. For the full year, CapEx was $33.7 million, primarily to support new product introductions and maintenance needs.
Cash Conversion Days (Q4) 85 days, compared to 100 days in Q4 of fiscal 2024 and 99 days last quarter. This represents the lowest CCD in 3 years, driven by improvements in all components of the calculation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Medical Facility: A new 300,000 square foot medical facility in Indianapolis was announced, aimed at expanding production capabilities beyond traditional printed electronics and circuit board assemblies to include cold chain management, complete device assembly, and precision molded plastics.
Medical Product Expansion: Current manufacturing includes medical disposables, single-use surgical instruments, and selected drug delivery devices such as auto-injectors. Plans to expand into cardiology, orthopedics, minimally invasive surgery, and surgical instruments and packaging.
Medical Market Growth: Medical sales grew 5% year-over-year in Q4, driven by increased sales with the largest medical customer. The company was selected as the sole supplier for respiratory care final assembly and higher-level assemblies, with production in Thailand.
Automotive Market Decline: Automotive sales declined 13% year-over-year in Q4 due to the loss of an electronic braking program in Reynosa, partially offset by a ramp-up of a similar program in Romania.
Industrial Market Stability: Industrial sales declined 12% year-over-year in Q4, with early signs of stability in climate control systems but offset by declines in other industrial segments in North America and Europe.
Cost Structure Adjustments: Significant cost reductions achieved, including a 23% reduction in adjusted selling and administrative expenses in Q4 compared to the previous year.
Working Capital Management: Six consecutive quarters of positive cash flow, with cash conversion days reduced to the lowest level in three years. Inventory reduced by 19% year-over-year.
Debt Reduction: Debt reduced by 50% year-over-year, reaching the lowest level in three years.
Focus on Medical CMO: Intensified focus on becoming a medical contract manufacturing organization (CMO), leveraging expertise in regulated and complex manufacturing environments.
Long-term Growth Strategy: Plans to pursue growth with blue-chip customers, emphasizing long product life cycles and high visibility. Exploring both organic and inorganic growth opportunities in the medical CMO space.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The company faces an unpredictable environment, which could impact liquidity and investment opportunities.
Automotive Segment Decline: Net sales in the Automotive segment decreased by 13% year-over-year, driven by the loss of an electronic braking program and lower demand for electronic steering systems for EVs.
Industrial Segment Weakness: Net sales in the Industrial segment declined by 12% year-over-year, with broad-based declines in North America and Europe, offsetting stability in climate control systems.
Foreign Exchange Impact: While foreign exchange had a 1% favorable impact on sales, currency fluctuations remain a potential risk to financial performance.
Regulatory and Compliance Risks: The company operates in highly regulated industries, particularly in the medical sector, which could pose compliance and operational challenges.
Supply Chain and Cost Structure: The company is adjusting its cost structure to demand trends, but supply chain disruptions or inefficiencies could impact operations.
Revenue Concentration in Medical Segment: The Medical segment's growth is heavily reliant on a single large customer, which poses a risk if demand from this customer declines.
Economic Uncertainty: Broader economic uncertainties could impact demand across all segments, particularly in Industrial and Automotive.
Capital Expenditure Requirements: The company plans significant capital expenditures, particularly for the new Indianapolis facility, which could strain financial resources if not managed effectively.
Transition Year Risks: Fiscal 2026 is expected to be a transition year with a projected 2% to 9% decrease in net sales, which could impact profitability and investor confidence.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Fiscal 2026 Revenue Guidance: Net sales are projected to range between $1.35 billion and $1.45 billion, representing a 2% to 9% decrease compared to fiscal 2025. Adjusted operating income is expected to be between 4.0% and 4.25% of net sales.
Capital Expenditures for Fiscal 2026: Projected to be in the range of $50 million to $60 million, with approximately $30 million allocated to the new Indianapolis facility and the remainder for growth, automation, and maintenance.
Medical Business Growth: Modest growth is expected in the Medical segment, driven by increased production for respiratory care final assembly and higher-level assemblies, particularly at the Thailand facility. The company anticipates leveraging opportunities in cardiology, orthopedics, minimally invasive surgery, and connected drug delivery systems.
Automotive Business Outlook: A decline is anticipated due to the loss of a braking program in Reynosa, partially offset by ramp-up in Romania and monitoring of demand for electronic steering systems for EVs.
Industrial Business Outlook: Modest growth is expected, with early signs of stability in climate control systems offset by declines in other industrial segments in North America and Europe.
Margin Projections: Margins are expected to remain in line with fiscal 2025, with potential for improvement when top-line growth returns, supported by enhancements to the cost structure.
Long-term Growth Strategy: Focus on expanding the medical CMO business, including potential inorganic growth opportunities, to achieve higher EBITDA margins and long-term profitable growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: We invested $3 million in Q4 to repurchase 162,000 shares. Since October 2015, under our Board authorized share repurchase program, a total of $103.7 million has been returned to our shareholders by purchasing 6.6 million shares of common stock. We have $16.3 million remaining on the share repurchase program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you remind us the timing of when the new facility in Indianapolis will be ready and the potential revenue capacity of that building?
A:The grand opening of the Indianapolis facility is planned for November of this year. The facility is 300,000 square feet with significant capacity for growth, potentially handling hundreds of millions of dollars of business, and well in excess of $0.5 billion depending on program sizes.
Q:What about some other directions you've been considering in the past year, like industrial adjacencies?
A:The company is taking a strategic approach and has had discussions in the Industrial sector, but there is nothing to announce currently. In Automotive, the focus remains on steering and braking, which are seen as areas with great potential. Opportunities are seen across all verticals.
Q:What about tariffs in general for your global footprint?
A:The company is not typically the importer of record, which provides some protection. Tariffs are treated as a pass-through with customers. The company has taken proactive steps, such as leveraging its global network and qualifying alternative sources of supply in different countries to provide flexibility.
Q:Can you remind us what you were doing for the respiratory program the last time? Was it a similar type of arrangement?
A:Previously, the company was doing higher-level full and final assembly for the respiratory program. There have been no material changes to the contract terms, and the company is now the sole supplier for all manufacturing, including full and final assembly.
Q:Did you say that program was coming out of Thailand?
A:Initially, the relationship involved printed circuit board assemblies and some full and final assembly. Now, all manufacturing, including full and final assembly, will be supported solely by the company, and there is no second supplier.
Q:Debt levels here are pretty low. Is there a structural new low for cash conversion days? What initiatives are improving this?
A:The company is targeting a reduction in cash conversion days from 85 to around 75. Initiatives include offering AR factoring programs, supplier financing programs, and better controls over inventory terms and production planning. The industry is returning to normal after COVID-related disruptions.
Q:In terms of the margin improvement, is that mainly going to be driven by the operating margin?
A:Gross margin improvement is expected due to restructuring, capacity utilization efforts, and the shutdown of Tampa. Investments in IT innovation and business development will support future growth. Higher revenue and better capacity utilization are expected to drive higher margins, particularly after FY '26.
Q:Do you still expect adjusted SG&A to be around 3% of revenue?
A:Adjusted SG&A is expected to be around 3.5% of revenue, which is the historical level. It will not sustainably stay at 3%.
Q:What kind of changes are you making to the sales organization and go-to-market strategy for the Medical segment?
A:The company is hiring in business development and leveraging experienced leaders across the Medical vertical. A comprehensive marketing plan has been undertaken to support CMO efforts, and significant investments are being made in sales to drive business growth.
Q:Has the focus on the Medical segment changed your competitive landscape?
A:The company’s FDA experience and capability to handle drugs provide a competitive advantage, making it more attractive and sticky to customers. This differentiates the company from traditional competitors.
Q:Will there be a lot of automation in the new Indiana facility, and how will it affect margins?
A:The new Indiana facility will have significant automation, and the CMO segment is expected to be accretive to margins over time due to the characteristics of the space.
Q:Are there other pockets of strength expected in the Medical segment for this year?
A:Yes, incremental growth is expected in the Medical segment beyond the highlighted customer. Most new customers introduced in the last two years have been in this segment, and the shift to full assembly provides more opportunities.
Q:How are you prioritizing new customers versus expanding programs at existing customers or hoping for improved demand in existing programs?
A:The company is focusing on all three areas: hoping for improved demand in existing programs, aggressively pursuing new business, and expanding programs with existing customers. The Medical space is expected to see the biggest introduction of new customers.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding specific announcements or developments in the Industrial sector, stating only that discussions were ongoing. Additionally, responses about tariff strategies were somewhat vague, relying on general approaches like leveraging the global network and qualifying alternative sources without providing specific examples or data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CCD
Capital
Cash
EMS
Kimball Electronics
LLC
Research Division
assembly
braking program
capital
cash flow
cost structure
device
drug delivery
expectation sale
expenditure
expense
facility Indianapolis
improvement
income sale
instrument
inventory sale
level year
line FY
opportunity
portfolio
precision
program Reynosa
reduction
share
subsidiary
system
tax rate
KE Transcript
Kimball Electronics, Inc. (KE) Q3 2026 Earnings Call Transcript
Positive5-6
The earnings call summary highlights a strong financial performance with a 10% revenue increase and improved gross margins, leading to a 15% rise in net income. The positive financial metrics, along with increased operating cash flow, suggest a healthy financial position. Despite the absence of detailed strategic initiatives, the financial results and raised guidance for fiscal 2026 are likely to result in a positive stock price movement. However, the lack of additional insights from the Q&A section and strategic updates tempers the rating to 'Positive' instead of 'Strong positive.'
Kimball Electronics, Inc. (KE) Q2 2026 Earnings Call Transcript
Unknown2-5
The earnings call presents a mixed picture: strong growth in the medical segment and improved gross margins are positive, but overall net sales declined, and automotive sales are down. The shareholder return plan is positive, but the Q&A reveals uncertainties about the new facility's impact on margins and revenue. The market reaction is likely to be neutral, with offsetting positive and negative factors balancing each other out.
Kimball Electronics, Inc. (KE) Q1 2026 Earnings Call Transcript
Unknown11-6
The earnings call highlights a mix of positive and negative factors. Strong adjusted income and net income, debt reduction, and cash flow are positives. However, the guidance for fiscal 2026 indicates revenue decline and modest growth in key segments. The Q&A reveals positive sentiment towards medical growth and strategic acquisitions, but concerns in the automotive sector and potential SG&A increase. Overall, the outlook is mixed with stable margins and strategic growth plans, leading to a neutral sentiment.
Kimball Electronics, Inc. (KE) Q4 2025 Earnings Conference Call Transcript
Positive8-14
The earnings call highlights a robust strategy with new facility expansion, strong focus on the medical segment, and margin improvement efforts. The Q&A reveals positive sentiment towards automation and growth initiatives, despite some vague responses on industrial plans. The reiteration of fiscal guidance, coupled with strategic investments in sales and business development, supports a positive outlook. The absence of negative financial surprises and the focus on high-growth segments suggest a positive stock price movement in the short term.
KE Slides
KE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
